Overview

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Status:
Approved for marketing
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
Details
Lead Sponsor:
Novartis
Treatments:
Capecitabine
Lapatinib